Canada markets closed

EyeGene Inc. (185490.KQ)

KOSDAQ - KOSDAQ Delayed Price. Currency in KRW
Add to watchlist
2,995.00-135.00 (-4.31%)
At close: 03:30PM KST

EyeGene Inc.

B-1211, 401 Yangcheon-ro
Gangseo-gu
Seoul 07528
South Korea
82 2 322 1687
https://www.eyegene.co.kr

Sector(s)
Industry
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Yang-Je ChoCo-Founder and Chief Technology OfficerN/AN/AN/A
Soobeom LeeChief Financial OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster. In addition, the company provides vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Corporate Governance

EyeGene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.